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Cardiovascular disease (CVD) is the largest 
cause of mortality in the world with around 
17.7 million victims each year 1 CVDs 
include coronary heart disease, ischemic 
heart disease, rheumatic heart disease, 
cardiomyopathies, and other diseases 
involving the heart and circulatory system. 
However, in contrast to the progress made in 
high-income countries, the burden of CVD 
and other noncommunicable diseases have 
only continued to rise significantly in low and 
middle-income countries, especially India. It 
is estimated that nearly 80% of CVDs will be 
burdened by developing countries by 
2020.2 Interestingly, India has been  
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disproportionately impacted by these CVDs. 
In India, the average age of 59 for heart 
failure patients is approximately ten years 
younger than the average age for heart failure 
(HF) patients in South America and 
China 3 In contrast to most western countries, 
HF is prevalent in both the young and elderly 
in India.4 Moreover, India’s estimated age-
standardized death rate of 272 per 100,000 
population due to CVDs is greater than the 
global average of 235 per 100,000 
population5Both environmental and genetic 
factors are argued to contribute to this 
increased CVD susceptibility. 6 India has 
begun to research and implement innovative 
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policies and interventions to help tackle this 
and achieve the WHO target goal of a 25% 
reduction in premature deaths from 
noncommunicable diseases by 2025. 
General Policies and Interventions 
Policies and interventions for CVDs that can 
be adopted and successfully implemented in 
India have been an area of high focus. These 
often target behavioral risk factors (tobacco 
use, excessive alcohol intake, physical 
inactivity, poor dietary consumption, etc.), 
social determinants of health, and acute and 
chronic CVD care. Success of these 
interventions is dependent upon cross-
collaboration between various industries 
within the private and public sectors. 
Policies involving tobacco regulation have 
been effective in high-income countries, 
leading to India passing the Cigarettes and 
Other Tobacco Products Act (COTPA) in 
2003, which includes prohibited public 
smoking, mandated health advisory labels, 
and restricted tobacco advertising.7 Other 
food and environmental interventions that 
have been implemented in India or shown 
promising elsewhere for use in India include 
increased taxation of different foods or 
drinks, subsidies for fruits and vegetables, 
and even usage of low-emission cooking 
stoves. 8 9Other general policies or 
interventions that have been of interest 
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include CVD awareness campaigns, 
increased preventive health screening, school 
education programs, expanded insurance 
coverage, increased funding for CVD 
research, and more. 
In regards to clinical treatments, the concept 
of a polypill, which is a combination of 
multiple drugs (aspirin, angiotensin 
converting enzyme (ACE) inhibitor, etc.) in a 
single capsule, has been of recent interest. 
The concept of polypills arose when experts 
realized that although multiple different 
medicines (e.g. antiplatelet agents, blood 
pressure lowering agents, etc.) individually 
served well in primary and secondary CVD 
prevention, many other issues such as 
adherence and access to these groups of 
medicines could be improved through a 
single capsule medication. Much research 
today is now focused on developing and 
improving these polypills due to promising 
results from many past and ongoing clinical 
trials in regards to improved medication 
adherence and access.10 However, although 
several of these polypills have become 
available, many physicians, such as those in 
India, have not been enthusiastic about using 
them, likely due to their lack of patient-
specificity.10  
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 Understanding India’s Challenges 
India’s rapidly growing population has led to 
a major shortage of doctors, especially those 
involved in cardiac care. Only around 4,000 
cardiologists were registered as of 2013 with 
the Cardiological Society of India (the largest 
cardiologist organization) for a growing 
population of nearly 1.3 billion 
people 11 12 The government needs to further 
develop India’s medical education 
infrastructure and reduce its associated 
expenses to allow for more students to pursue 
medicine and other health professions. 
Moreover, a majority of hospitals and 74% of 
graduate doctors are located in urban areas, 
thereby serving only 28% of the Indian 
population 13 These urban hospitals are very 
expensive, making affordable care difficult 
for many. This lack of doctors in rural areas 
has led to increasing numbers of unqualified 
providers prescribing and treating patients, 
putting many lives at risk. Financial or other 
incentives for investors, healthcare providers, 
and hospitals are needed to promote further 
expansion and development in rural areas. 
What further makes tackling CVDs in India 
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challenging is the large regional and ethnic 
diversity within the country. Differences in 
biological risk factors, access to proper care, 
adherence to treatments, and more may vary 
between different groups and regions, 
possibly due to religious, cultural, or social 
differences. Further research and careful 
consideration of these differences are critical 
for successful implementation of new 
interventions. 
Within India, social determinants have a 
major impact on CVD diagnosis, outcomes, 
and spending. The poor are more frequently 
under-diagnosed, have reduced access to 
proper care or medicines, and face a larger 
financial burden from CVDs 14, 15 Those of 
lower socioeconomic status (SES) are often 
less likely to have successful outcomes and 
receive different treatments compared to 
those of higher SES. For example, acute 
coronary syndrome patients of lower SES 
received different and less effective 
treatments than higher SES patients, which 
also likely contributed to their greater 
mortality rate.16 Policies that can reduce 
14 Agyemang, C., & van den Born, B.-J. (2018). 
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the matter. The Lancet Global Health, 6(3), e234–
e235. https://doi.org/10.1016/S2214-109X(18)30048-
2 
15 Vellakkal, S., Subramanian, S. V., Millett, C., 
Basu, S., Stuckler, D., & Ebrahim, S. (2013). 
Socioeconomic Inequalities in Non-Communicable 
Diseases Prevalence in India: Disparities between 




16 Xavier, D., Pais, P., Devereaux, P. J., Xie, C., 
Prabhakaran, D., Reddy, K. S., … CREATE registry 
investigators. (2008). Treatment and outcomes of 
acute coronary syndromes in India (CREATE): a 
prospective analysis of registry data. Lancet (London, 
Harvard Public Health Review                   Puneet Gupta 
4 
 
medical expenses to improve access to high-
quality care for all socioeconomic classes 
will likely to lead to improved survival rates 
and a reduced CVD burden. 
 Marching Forward 
India’s growing population and large 
socioeconomic disparities allow it to serve as 
a strong model for implementing various 
CVD policies in other low and middle-
income countries. Successful CVD 
interventions in one of the most rapidly 
growing countries in the world will reduce 
the global health burden of CVDs and inspire 
other countries to take great strides forward 
as well. However, under-developed health 
infrastructures and insufficient proper 
resources make adoption of interventions and 
policies that have worked in high-income 
countries to lower and middle-income 
countries difficult. Nonetheless, it is 
imperative that India continues marching 
forward and invests resources into tackling 
the CVD epidemic in order to protect the 
health of its citizens and bring great 
prosperity to the country. 
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